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Abstract
Bioconjugates have been used to deliver therapeutic oligonucleotides to their pharmacological 
targets in diseased cells. Molecular-scale conjugates can be prepared by directly linking targeting 
ligands with oligonucleotides and the resultant conjugates can selectively bind to cell surface 
receptors in target cells in diseased tissues. Besides targeted delivery, additional functionality can 
be incorporated in the conjugates by utilization of carrier molecules, and these larger conjugates 
are called carrier-associated conjugates. Both molecular and carrier-associated conjugates have 
achieved initial successes in clinical trials for treating liver diseases; therefore, currently the 
greater challenge is to deliver oligonucleotides to extrahepatic tissues such as tumors. This review 
will provide an update on the application of oligonucleotide conjugates for targeted delivery 
during the last decade. By identifying key elements for successful delivery, it is suggested that 
oligonucleotide conjugates with intermediate size, cell targeting ability, and endosomal release 
functionality are superior systems to advance oligonucleotides to achieve their full therapeutic 
potentials.
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1. Introduction
Therapeutic oligonucleotides (ONs) provide opportunity for treating serious, life-threatening 
diseases with limited options using traditional small-molecule and antibody drugs. Those 
traditional medicines have been constrained by limited “druggable” targets. Small-molecule 
drugs can only target certain classes of proteins including G protein-coupled receptors, ion 
channels, enzymes, and nuclear hormone receptors [1], while the targets for antibody drugs 
are limited to cell-surface receptors and circulating proteins. In contrast, antisense and 
siRNA ONs can modulate the expression of any gene and thus can target any protein by 
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inducing enzyme-dependent degradation of target mRNAs [2]. Further, steric-blocking ONs, 
including splice switching ONs (SSOs), and antagomers of microRNAs and long non-
coding RNAs, block the access of cellular machinery to pre-mRNA or mRNA without 
causing enzymatic degradation of the RNA [3, 4]. Through this mechanism, steric-blocking 
ONs can target non-coding RNAs that exert important regulatory controls on many 
biological processes [5] . Thus, the target space for ONs is even larger than the size of 
human proteome. Indeed, the positive outcomes from the clinical trials of microRNA 
antagomirs [6] and SSOs [7, 8] have revealed the tremendous therapeutic potentials for ONs 
by targeting non-coding RNAs that are “undruggable” by small molecules and antibodies. 
Despite the enormous therapeutic potential, the development of ONs as therapeutic agents 
has been constrained by the inability of these membrane-impermeable molecules to reach 
their intracellular sites of action. Indeed, the FDA-approved antisense drug Mipomersen [9] 
and several other ONs in late-phase clinical trials [6, 10, 11] target the genes in the liver 
although ONs can also modulate extrahepatic targets. This limitation is largely due to the 
favorable physiology of the liver, being a well-perfused organ with a fenestrated 
endothelium, and endogenous ability of the hepatocytes to take up ONs and/or their delivery 
systems [12, 13]. Therefore, the success of ON delivery to intracellular targets in disease 
sites determines whether ONs can meet therapeutic demands that are unmet by traditional 
medicines.
Therapeutic ONs must overcome numerous biological barriers to reach their intracellular 
targets following systemic administration [12, 14] (Fig 1). After administration, ONs must 
avoid rapid degradation by nucleases in the bloodstream and fast clearance via the 
reticuloendothelial system and renal filtration. Then they need to cross the vascular 
endothelial barrier and diffuse through the extracellular matrix to approach the diseased cells 
in tissue. Chemical modification has improved nuclease stability of ONs and thereby their 
circulation half-life [12]. However, precise delivery to the cells of interest in disease tissues 
remains a key hurdle for the widespread use of therapeutic ONs [12, 14]. Size has a 
substantial impact on pharmacokinetics and biodistribution of ONs and their delivery 
systems. Materials with a size larger than 10 nm may have long circulation time in blood 
because of reduced renal filtration [12]. However, larger particles (>50 nm) may only access 
tissues where the vasculature is leaky, such as liver, spleen and some tumors [12, 15]. Thus, 
delivery systems with intermediate size (10-50nm) may have better chance to deliver ONs to 
diseased tissues. Even reaching diseased sites, ONs have to cross the plasma membrane and 
the endosomal membrane to access their target genes in the cytoplasm and/or nucleus of 
cells. Overcoming these cellular barriers is generally considered as the rate-limiting step for 
these membrane-impermeable molecules to reach their intracellular sites of action [12, 14].
There have been two broad approaches to the delivery of ONs besides administration of free 
ONs. One has been to incorporate ONs into various lipid or polymer nanocarriers [16-22]. A 
second approach has been to create molecular-scale or macromolecular conjugates where 
ONs are linked to ligands that can bind with high affinity to specific cell surface receptors 
thus promoting entry via receptor-mediated endocytosis [13, 23]. Chemical conjugation of 
targeting ligands and ONs produces well defined molecules that are physically stable and 
enjoy relatively broader tissue distribution than nanoparticles (NPs) [12]. Thus, ON 
conjugates may have better chance to realize potentials of ONs by accessing a broader 
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pharmacological target space. This review will provide an update on the progress of ON 
conjugates for delivery and highlight the mechanisms underlying functional delivery of the 
ON conjugates. The objective of this review is to motivate more rational strategies leading 
to greater clinical successes of therapeutic ONs.
2. Molecular conjugates
The simplest method to prepare ON conjugates is to directly link peptide, lipid, 
carbohydrate, or small molecule moieties at the 5′ or 3′ positions of ONs so as to provide 
selective binding to cell surface receptors in target cells. Conjugation of a ligand should not 
interfere with binding of the ON to its RNA target and the post-binding events. Single-strand 
ONs are more tolerable to modification as long as the ligands are relatively small [24-26]. In 
contrast, modification of the antisense strand of siRNA, especially its 5′-terminus, should be 
avoided because the 5′-terminus of the antisense strand must be phosphorylated to be 
recognized by the RNA-induced silencing complex [27]. A variety of linkages have been 
used to conjugate ligands and ONs including amide, thioether, thiol-maleimide, ester, and 
disulfide [23, 28, 29]. Some linkages are readily cleavable inside the cells, including 
disulfide, some peptides, and hydrazone, and they are needed to attain biological activity of 
ONs when large ligands such as antibody [30] or carrier proteins such as albumin [31] are 
linked the ONs.
Cell selective delivery through ligand conjugation depends on the binding affinity of the 
ligands to their receptors and the density of the receptors on the target cell surface [32]. 
Besides, the intrinsic uptake rate of the ONs also plays a role. “Free” phosphorothioate (PS) 
ONs can bind to membrane receptors and enter the cells via endocytosis [13], and their 
cellular uptake is more efficient than “free” siRNA ONs and neutral morpholino ONs. 
Therefore, integrin targeting RGD peptide modified siRNA showed about 20-folded higher 
uptake than “free” siRNA in cancer cells [33], while RGD modified PS ON only showed 
about 2-fold higher uptake than free SSO [26].
2.1 Carbohydrate-ON conjugates
The leading ON conjugate in clinical development is a carbohydrate-siRNA conjugate 
composed of chemically stabilized siRNA with a trivalent liver-targeting ligand [34]. 
Developed by Alnylam Pharmaceuticals, three siRNA conjugates targeting different liver-
expressed genes are currently in Phase I/II clinical trials for the treatment of transthyretin 
amyloidosis, hypercholesterolemia and haemophilia, respectively (www.clinicaltrials.gov). 
In this conjugate, the 3′ terminus of the siRNA sense strand is linked to three molecules of 
N-acetylgalactosamine (GalNAc), an asialoglycoprotein receptor ligand, by means of a 
triantennary spacer (Fig 2) [34]. Asialoglycoprotein receptor, mainly expressed in the 
hepatocytes, binds and then mediates endocytosis of the galactose-terminal glycoproteins, in 
order to remove them from circulation [35]. This receptor has been considered as one of the 
most promising membrane proteins for hepatic delivery since it exhibits high affinity and a 
rapid internalization rate via the clathrin-mediated pathway [35]. In addition, it is easy to 
couple the GalNAc ligands to ONs as the ligand conjugation step can be incorporated in the 
process of solid-phase synthesis of ONs [34]. Another advantage of GalNAc-siRNA 
conjugates is that subcutaneous administration of GalNAc-siRNA conjugates resulted in 
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robust gene silencing in liver with a median effective dose (ED50) of 1 mg/kg following a 
single dose, while lipid nanoparticles (LNPs) of siRNA can only be given intravenously 
[34]. The effective delivery via subcutaneous administration highlights the superior 
diffusibility of the small-sized conjugates and less non-specific interaction in the injection 
sites for the hydrophilic GalNAc-siRNA conjugates. The GalNAc-siRNA conjugates are 
hepatotropic and long-acting and thus have the potential to treat a wide range of diseases 
involving liver-expressed genes [34]. Besides GalNAc, mannose 6-phosphate, another 
carbohydrate, has been linked to siRNA for targeted delivery to hepatic stellate cells that 
play a central role in liver fibrosis [36].
2.2 Lipid-ON conjugates
Conjugation of siRNA or other ONs with a lipid tail has been shown to improve cellular 
uptake and in vivo pharmacokinetics of ONs [37-39]. This method, more specifically, 
conjugation of ApoB siRNA with cholesterol, led to the first example of gene silencing after 
systemic administration [38]. Cholesterol-siRNA conjugates can form particles with 
lipoproteins in blood circulation, which increases circulation time and promotes uptake into 
the hepatocytes via lipoprotein receptors [39]. The lipid-siRNA conjugates have been further 
optimized by using new lipids such as α-tocopherol [40] and by controlling the length of the 
linker between siRNA and lipid [41].
2.3 Small molecule-ON conjugates
Besides natural carbohydrate and lipids, small molecule drugs that demonstrate high binding 
affinity to their receptors have been used for ON delivery. Thus, mono- and multivalent 
conjugates of SSOs with anisamide, a small molecule ligand for the sigma receptor, have 
been synthesized and tested [42]. ONs have also been conjugated with folate [43] and with 
anandamide [44] that bind to the folate receptor and a cannabinoid receptor, respectively. 
All of these conjugates have shown to significantly enhance functional activity ONs in the 
absence of any transfection agent.
2.4 Peptide-ON conjugates
There are two types of peptides that have been used to ON delivery: cell-penetrating and 
cell-targeting peptides. Cell-penetrating peptides (CPPs) are the short basic amino acid-rich 
peptides, which can not only enter cells themselves but also facilitate the transport of 
molecular cargos across the plasma membrane. Many types of CPPs, including prototypical 
CPPs and those selected from structure-activity studies, have been directly linked to 
siRNAs, ASOs, and SSOs for in vivo delivery [45-47]. CPP conjugation has achieved more 
successes in delivery of SSOs, particularly uncharged morpholino or peptide nucleic acid 
oligomers. CPP-SSO conjugates have been used to correct defects involved in Duchenne 
muscular dystrophy and have shown good effects both in cell culture and in dystrophic mice 
[48-50]. CPP-based delivery of ONs is further discussed in a review by Boisguérin et al. in 
this theme issue.
Cell-targeting peptides are ligands for specific receptors that are overexpressed in diseased 
sites [32], and targeting peptide-ONs can provide additional disease selectivity compared to 
CPP-ON conjugates. siRNAs, ASOs or SSOs have been conjugated with peptides designed 
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to bind to specific receptors, for example, integrin αvβ3 [26, 33, 51, 52], bombesin receptor 
[53], and insulin-like growth factor 1 receptors [54, 55]. Conjugates of ONs with integrin-
targeting RGD peptide have been the most studied peptide-ON conjugate. In one study, 
siRNA was linked with mono-, bi-, tri-, and tetravalent cRGD peptides. The bi-, tri-, and 
tetravalent cRGD conjugates were taken up by integrin αvβ3 positive M21+ human 
melanoma cells at approximately the same rate. However, only the tri- and tetravalent 
versions produced RNAi activity, while the bivalent version had little effect [33]. One cause 
of this disaccord may be the distinct internalization pathways that the peptide-ON 
conjugates undertake.
A recent development in peptide-ON conjugates was the use of chimeric peptides composed 
of multiple peptide domains with different functionalities. In one study, linking a muscle-
specific peptide to a CPP peptide further improved the in vivo delivery of the CPP-SSO 
conjugate, producing functional correction of dystrophin and thereafter the improvement of 
the dystrophic phenotype [56]. In another study, peptides that include bombesin sequences 
for receptor targeting and a run of histidine residues for endosomal disruption were 
covalently linked to a SSO, and a trivalent version of this conjugate was prepared by means 
of a triantennary linkage. The trivalent conjugates that included both the targeting sequence 
and several histidine residues were substantially more effective than conjugates containing 
only the bombesin or histidine moieties, indicating the potential of creating molecular scale 
ON conjugates with both targeting and endosome escape capabilities [57].
2.5 Antibody-ON conjugates
Antibodies have been the primary choice as targeting moieties in targeted drug delivery and 
antibody-drug conjugates have achieved tremendous clinical success for cancer therapy [58]. 
This approach of direct conjugation has been extended to ON delivery; however, direct 
antibody-ONs conjugates haven't accomplished similar success as antibody-drug conjugates. 
In one study, a humanized monoclonal antibody was linked to siRNA via a reductive 
disulfide bond that is cleavable within cells [30]. Although antigen-specific binding and 
internalization of the antibody-ON conjugates were observed, single treatment of the 
conjugates failed to produce significant gene silencing. Co-treatment with chloroquine, an 
endosomal release reagent, caused RNAi activity, which indicated that functional delivery of 
the conjugates was limited by poor endosomal release [30]. Endosomal trapping of the 
antibody-ON conjugates was demonstrated by another study in which bispecific antibodies 
were used for binding to cell surface antigens with one binding domain and carrying 
antigen-modified siRNA with another domain [59]. Again, effective antigen-specific 
delivery of the antibody-siRNA conjugates did not lead to RNAi activity as the conjugates 
were not released from the endosomes. Formulating the conjugates into dynamic 
polyconjugates (DPCs) or into LNPs produced strong RNAi activity both in vitro and in vivo 
[59]. Although direct antibody-ON conjugates haven't achieved ideal therapeutic activity, 
those constructed via cationic carriers such as protamine have shown success both in vitro 
and in vivo. We will discuss this in Section 3.2.
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2.6 Aptamer- and CpG-ON conjugates
Nucleic acid aptamers are single-stranded ONs with tertiary structures that bind to specific 
target molecules [60]. They are usually selected from pools of random-sequence ONs using 
an approach called Systematic Evolution of Ligands by Exponential Enrichment (SELEX). 
Aptamers not only bind to cell surface receptors to produce therapeutic activity by blocking 
the receptor, but also can enhance the endocytosis of cargo molecules that are linked to the 
aptamers, thereby acting as carrier molecules to deliver intracellular therapeutics, including 
drugs, toxins, and ONs [61].
Initial studies of aptamer-based ON delivery have targeted prostate-specific membrane 
antigen (PSMA), a protein that is expressed on the surface of some prostate cancer cells 
[62]. In one of the studies, biotin-labeled PSMA-specific aptamer and siRNA were linked 
via streptavidin and the conjugate produced RNAi activity specifically in PMSA positive 
cells [63]. Another study showed that two siRNAs, which were fused covalently to a PMSA 
aptamer, also targeted PMSA positive cells, and inhibited growth of prostate cancer 
xenografts following intratumoral injection [64]. The aptamer-siRNA chimeras have been 
optimized for extended plasma half-life by, for example, adding a terminal PEG, and the 
resultant conjugate showed potent antitumor activity after systemic injection into mice [65]. 
In addition, aptamer-siRNA chimeras of gp120-specific aptamer and a siRNA target HIV 
infected cells, and inhibit HIV replication through aptamer-mediated receptor blocking and 
RNAi activity [66, 67].
In another example of ONs as delivery agent, the siRNA targeting the immune suppressor 
gene Stat3 was linked to an immunostimulatory CpG ON to stimulate an anticancer immune 
response [68]. The binding of CpG-siRNA conjugate to the toll-like receptor 9 (TLR9) in 
immune cells not only caused various immune responses via endosomal TLR activation, but 
also triggered the internalization of the siRNA conjugate, leading to Stat3 silencing for 
greater antitumor immune response [68]. The CpG-siRNA conjugate was observed to first 
enter early endosomes, where CpG and siRNA parts of the conjugate are uncoupled by 
Dicer [69]. Diced siRNA molecules are then translocated to endoplasmic reticulum, where 
TLR9 facilitates release of the diced siRNA to interact with the RNAi machinery [69]. These 
findings suggest that the class of immunostimulatory siRNAs may benefit from activation of 
certain endosomal immune receptors, such as TLR9, by enhancing RNAi activity and 
synergistic therapeutics [69].
3. Carrier-associated conjugates
Besides cell selective delivery, additional functionality is often required for ON conjugates, 
including long circulation time and effective endosomal release. A carrier molecule can be 
used to achieve multiple functionalities and the resultant conjugates are significantly larger 
than free ONs. We call this type of ON conjugates as carrier-associated conjugates.
3.1 Polymer as carriers
Polymers are often used to link to ONs to improve their therapeutic activity, for example, 
PEGylation is often used to increase the size of the ONs and thus increase the circulation 
half-life of the therapeutic ONs via reduced renal filtration [65]. In addition, amphipathic 
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polymers, which are capable of disrupting cell membrane, are often incorporated in the ON 
delivery systems for improving endosomal release of ONs.
The leading ON-polymer conjugate in clinical development is Dynamic Polyconjugates 
(DPCs) [70], which is currently being tested in a Phase II clinical trial for the treatment of 
Hepatitis B (www.clinicaltrials.gov). This delivery system is composed of several 
components, each designed to play a particular role in the siRNA delivery (Fig 3). The 
carrier molecule poly(butyl amino vinyl ether) (PBAVE) has side chains including alkyl 
groups interspersed with amines and thus this amphipathic polymer can disrupt cell 
membranes [70]. The membrane-disrupting activity of the polymer is masked by PEG via 
acid-cleavable carboxylated dimethyl maleic acid (CDM), and liver-targeting GalNAc 
ligands are also linked to the PBAVE polymer via this chemistry [70]. Further, the siRNA 
cargo is attached to the polymer by the bioconvertible disulfide bond. The PEG and the 
ligand are designed to be shed in the acidic environment inside the endosome, exposing the 
membrane-active polymer and triggering endosomal release; the disulfide linkage is cleaved 
in the reducing environment of the cytosol, releasing the siRNA from the polymer [70]. This 
polymer-based system with both cell targeting and endosomal releasing abilities was 
specifically delivered to hepatocytes after IV injection and produced effective gene 
knockdown and therapeutic activity in mice [70].
The original DPCs have been optimized by Arrowhead Research Corporation and other 
groups. Scientists at Merck & Co. Inc have focused on optimization of the carrier polymer in 
order to enhance the efficacy and safety of the delivery system [71-73]. The amphipathic 
PBAVE polymer in original DPCs may continue to interact with non-endosomal membranes 
after endosomal release and then cause side effects. Thus, in one study, disulfide bonds were 
incorporated in the backbone of the amphipathic polymers, and the resultant poly(amido 
amine disulfide) polymers provided degradability through reduction by glutathione in 
cytosol. Thus, the new DPCs of siRNAs produced excellent gene silencing in vitro and in 
vivo and did not cause significant toxicity [73]. In another study, by incorporating low pKa 
heterocycles, acid cleavable amino side chains, or carboxylic acid pH sensitive charge 
switches, the membrane activity of the polymers were triggered by the acidic environment 
inside the endosome and were then abolished after release into neutral environment in the 
cytosol. Thus, in animal studies, the new DPCs dramatically increased the therapeutic index 
to 10-15 from less than 3 for their original version [72].
A different strategy has been adapted to advance DPCs to clinical trials at Arrowhead 
Research Corporation. Instead of covalent attachment of siRNA to masked polymer in the 
original system, GalNAc-modified DPC polymer and cholesterol-conjugated siRNA are co-
administered to target the same hepatocytes in the liver (Fig 2) [74]. The new delivery 
approach increased the efficacy over 500-fold over single use of cholesterol-siRNA and 
allowed over 90% reduction in target gene expression in mice and non-human primates [74]. 
A further optimization involves replacement of the synthetic polymer with a melittin-like 
peptide with similar endosome-specific lytic properties, which further simplified the 
preparation of the delivery system and simultaneously enhanced the siRNA delivery [75, 
76]. The new system achieved excellent efficacy (ED50 = 0.01 mg/kg siRNA) in mice and 
nonhuman primates without causing significant toxicity after IV administration [75]. 
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ARC-520, siRNA therapeutics that are delivered by this co-injection approach [76] are in a 
Phase II clinical trial for treating Hepatitis B (www.clinicaltrials.gov).
3.2 Protein as carriers
Human serum albumin (HSA) has a long history as a biodegradable, nontoxic carrier for 
small molecule and peptide drugs [77, 78]. With a diameter of ∼7nm that is close to the pore 
size of the glomerular filtration barrier, HSA exhibits minimal renal clearance and thus 
enjoys a long circulation half-life of 19 days [79]. Thus, albumin is an ideal carrier to 
increase the circulation half-life of drugs and ONs. Albumin has been used as carrier for 
targeted delivery of ONs [31, 80]. In one study, the SSOs are linked to albumin via 
reversible disulfide bonds. The albumin is also conjugated with PEG chains that terminate in 
an RGD ligand [80]. In a similar but simplified design, a morpholino ON was conjugated to 
a RGD peptide, and then, multiple RGD-ON conjugates were linked to a single molecule of 
HSA via disulfide bonds (Fig 4) [31]. Both methods produced small NPs with uniform and 
monodispersed size distribution at a diameter of 12-13nm, which may be a favorable size for 
long circulation time [31, 80]. The intermediate sized HSA-ON conjugates could penetrate 
deeply and distribute throughout 3-D tumor spheroids (Fig 4), whereas the conventional NPs 
with sizes over 300 nm could only deliver to the cells on the surface of the tumor spheroids 
[31, 81, 82]. Utilization of HSA as carrier enabled displaying multiple (10-15) targeting 
ligands on the surface of the NPs, and this dramatically enhanced receptor-specific cellular 
delivery of ONs in integrin-expressing cancer cells (Fig 4). The targeted HSA-ON 
conjugates thus increased functional activity of the ON at low nanomolar concentrations 
without causing cytotoxicity [31, 80]. These delivery systems did not contain any endosomal 
release functionality yet. Thus, when the cells were further treated with Retro-1 that can 
cause endosomal release in the cells [83], functional delivery of ONs could be further 
enhanced by 5-fold [31].
Another protein carrier for ON delivery is a dsRNA binding domain. This protein is used for 
CPP-mediated delivery of siRNA. CPP conjugates with neutral ONs such PMOs and PNAs 
are more successful than those with negative charged ASN and siRNAs. The underlying 
cause may be the decrease of the net positive charge after conjugation of CPPs to 
polyanionic ONs. Thus, Tat CPP has been fused to a dsRNA binding domain, which binds 
siRNA tightly and masks their negative charges so as to allow CPPs to exert its membrane 
penetration ability [84]. This novel construct led to functional delivery of siRNA to tumors 
in vivo [84].
Protamine is a cationic protein that delivers siRNAs by binding them via noncovalent charge 
interaction. As one example, a single-chain antibody is fused with protamine, which binds 
siRNAs and forms a targeted delivery system [85, 86]. Antibodies targeting several 
membrane markers of tumors or lymphocytes have been utilized to deliver siRNAs to the 
tumors and HIV infected lymphocytes, which led to RNAi activity and effective therapeutics 
after systemic administration [85, 86]. Along the same line, an antibody has been fused with 
positively charged Oligo-9-arginine peptide, and thereby bound siRNAs targeting multiple 
viral proteins [87]. Systemic administration of the siRNA conjugates to HIV infected mice 
has achieved viral suppression [87]. As direct antibody-ON conjugates failed to produce 
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RNAi activity without using endosomal release reagents, it is believed that the cationic 
protamine and Oligo-9-arginine peptide may enhance endosomal release of the ONs [30].
3.3 DNA NPs as carriers
As we consider the range of carriers being investigated for the delivery of ON therapeutics, 
the ON itself is emerging as a viable option with uniquely suitable properties. Self-
assembled nanostructures derived from nucleic acids (DNA and RNA) are increasingly 
being employed as agents for delivery of functional ONs and show significant promise for 
overcoming the current barriers to ON delivery [88-90]. In comparison to other methods, 
DNA nanotechnology is a highly efficient and controllable strategy for creating structures of 
defined shape and size through rational design and construction [91]. These DNA 
nanostructures with different sizes, shapes, and geometries have characteristic uniform size, 
precise addressability, excellent water solubility, and biocompatibility. Hence, they offer 
new opportunities for construction of nanostructures for biomedical applications.
DNA and RNA nanostructures are well suited for targeted drug delivery applications and 
offer the advantage of controlling the valence and geometry of attached targeting ligands. 
Nucleic acids based nanostructures can be functionalized or conjugated to a wide range of 
targeting ligands including small molecules, aptamers, peptides and antibodies. Several 
recent reports have described utility of 3-dimensional DNA and RNA caged structures for 
targeted delivery. Li et al reported a tetrahedral nanostructure appended with multivalent 
CpG ONs were effective in targeting TLR9 and producing an immunostimulatory response 
[92]. Guo and co-workers, working with modified multivalent pRNA nanostructures 
demonstrated targeted delivery of siRNA through folate receptor targeting [93, 94]. A recent 
report by Charoenphol and Bermudez described the successful use of DNA tetrahedron 
decorated with AS1411, an aptamer targeting the nucleolin receptor, and showed enhanced 
inhibition of tumor cell growth [95]. The Anderson group also utilized a DNA tetrahedron 
for siRNA delivery in an in vivo mouse model using tumor targeting folic acid [91]. In this 
study, DNA NPs allow precise control of the number and arrangement of these ligands, and 
interestingly the NPs carrying 3 folate ligands but at different positions had the same rate of 
cellular uptake, but produced diverse RNAi activity, leading to a rationale that their 
arrangement might affect the intracellular trafficking of the NPs.[91] The examples 
described here show the increasing use of nucleic acid based nanostructures for delivery of 
functional nanostructures.
3.4 Inorganic NPs as carriers
Inorganic NPs such as gold NPs have been used as nanocarriers for ON delivery. The so-
called “spherical nucleic acids (SNAs)” are polyanionic structures comprised of densely 
packed and highly oriented ONs that are attached to the surface of gold NPs via metal-thiol 
dative bonds. These NPs can effectively enter more than 50 different cell types without the 
aid of transfection agents and are able to produce antisense and RNAi activity [96]. In 
addition, topical application of SNAs carrying EGFR siRNA for 3 wks to mouse skin 
abolished EGFR expression and reduced epidermal thickness by 40% [96]. Mechanism 
studies have been followed to elucidate endocytosis pathways of SNAs [97, 98]. The latter 
study took advantage of great resolution of gold particles under transmission electron 
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microscopy and molecular tools that can manipulate endocytotic process. It demonstrated 
that the SNAs can bind strongly to class A scavenger receptors and undergo rapid cellular 
uptake via a lipid-raft-dependent, caveolae-mediated pathway. Evidence also showed that 
the SNAs enter early endosomes. However, it's still unclear on how they traffic after early 
endosomes and more importantly how they exit from the endosomal compartment. The 
original SNAs lack cellular selectivity, and thus a HER2 antibody was displayed on the 
surface of SNAs by conjugating the antibody with a complementary DNA sequence and 
binding to the SNAs. The resultant NPs produced cell-selective delivery and enhanced 
RNAi activity in HER2 positive cells [99].
Unique optical properties of some inorganic NPs via strong surface plasmon resonance 
absorption at visible and near-infrared wavelengths can produce photothermal effects to 
trigger endosomal release as well as release of ONs from the carriers [100]. In a study, 
hollow gold nanospheres with a size of 40nm were used for “photothermal transfection” of 
siRNAs toward cancer cells [101]. Both siRNA and folate ligands were linked to gold NPs 
via metal-thiol dative bonds. Targeted NPs exhibited significantly higher tumor uptake in 
tumor xenografts after I.V. administration. Cytoplasmic delivery of siRNA was triggered by 
light irradiation through photothermal effect, and thus RNAi activity was achieved only in 
tumors irradiated with light, but not in nonirradiated tumors, liver, spleen, kidney, and lung 
in the same mice, in spite of significant uptake of the siRNA NPs in these tissues. Thus, 
“photothermal transfection” of siRNAs via gold NPs may have advantage of low side effect 
[101].
4. Conclusion
Therapeutic ONs are delivered to their pharmacological targets in diseased tissues using free 
ONs, ON conjugates, or NPs. All three forms have achieved effective delivery to the liver 
and have led to FDA approval of the antisense drug Mipomersen [9] and several promising 
late-phase clinical trials. Thus, the greater challenge facing ON therapy is to deliver ONs to 
extrahepatic tissues including tumors, fibrotic tissues, heart, and muscle. Due to the lack of 
the favorable physiology and endogenous ON uptake ability, it is difficult to achieve 
effective intracellular ON concentration in those tissues by simply adapting liver delivery 
systems. Thus, the delivery systems for extrahepatic targets have to be further optimized and 
they must have three elements. First, they must have optimum size for long circulation and 
effective tissue penetration. Secondly, they must have cell targeting ability which enhances 
tissue accumulation and, more importantly, enables cell selective delivery. Thirdly, 
endosomal release functionality should be incorporated in the delivery systems.
Direct conjugates such as GalNAc-siRNA conjugates have achieved great success in liver 
delivery of ONs. Compared to larger NPs and carrier-associated conjugates, molecular 
conjugates are easy to prepare and may not have problems such as immunogenicity and 
biocompatibility that often hinder development of macromolecular drugs. Targeted ON 
conjugates can be easily changed to aim to extrahepatic tissues using other targeting ligands. 
However, single application of ligand-ON conjugates may not achieve functional activity in 
extrahepatic tissues in a similar level that was demonstrated in the liver. First, GalNAc-
siRNA conjugates have similar size to free siRNA, indicating possible fast renal filtration. 
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Circulation half-life of GalNAc-siRNA conjugates has not been reported; however, about 
half of the dose was accumulated in the liver [102], which is likely due to well-perfused 
liver and GalNAc targeting. In a less perfused organ, similar tissue accumulation of ONs is 
not expected; especially in that situation the liver is a non-target organ and may unfavorably 
trap ligand-ON conjugates. When low intracellular level is expected for extrahepatic 
application of ON conjugates, incorporation of endosomal release functionality becomes 
necessary. Indeed, fusion peptides of targeting domain and endosomal disruption domain 
have been reported [57]. Another strategy could be co-administration of endosomal reagents 
with ligand-ON conjugates, such as DPC polymers [75] and small-molecular ON action 
enhancers [83].
Carrier-associated conjugates provide several advantages over molecular conjugates and 
conventional NPs. Firstly, they are within the intermediate sizes (10-50nm) that are 
favorable to long plasma circulation and effective tissue penetration. The examples include 
polymer-ON conjugates (∼10nm) [70], HSA-ON conjugates (12-13nm) [31, 80], DNA NPs 
(20nm) [103], and gold NPs (∼40nm) [100]. Secondly, by using carrier molecules, multiple 
ligands can be displayed on the surface of the larger conjugates and thus superior targeting 
can be achieved. For example, HSA-ON conjugates that displayed 10 RGD ligands on the 
surface achieved significantly greater functional delivery of the model ONs than a direct 
RGD-ON conjugates only carrying a bivalent RGD peptide [26, 80]. Further, by precise 
positioning of targeting ligands using DNA NPs, favorable intracellular trafficking and 
superior functional activity can be achieved [91]. Thirdly, endosomal release functionality, 
including DPC polymer and photothermal materials, can be incorporated in the delivery 
systems for a precise co-delivery. Taken together, carrier-associated conjugates with 
intermediate size, cell targeting ability, and endosomal release functionality are superior 
systems to deliver ONs to extrahepatic targets.
Advance in ON-based therapeutics will continue to benefit from new delivery technologies 
and new materials. On the other hand, elucidating the underlying mechanisms leading to 
successful ON delivery will motivate rational design of new generation of delivery systems. 
Both will continue to advance therapeutic ONs to achieve the full therapeutic potentials.
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Abbreviations
ASO antisense oligonucleotide
CDM carboxylated dimethyl maleic acid
CPP cell penetrating peptide
DPC dynamic polyconjugate
ED50 median effective dose
GalNAc N-acetylgalactosamine
LNP lipid nanoparticle
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PBAVE poly(butyl amino vinyl ether)
PS phosphorothioate
PSMA prostate-specific membrane antigen
RGD Arg-Gly-Asp
siRNA small interfering RNA
SSO splice-switching oligonucleotide
TLR9 toll-like receptor 9
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Biological barriers to systemic delivery of ON conjugates. After systemic administration, 
ON conjugates must avoid rapid degradation by nucleases in the bloodstream and fast 
clearance via the reticuloendothelial system and renal filtration. Then they need to cross the 
vascular endothelial barrier and diffuse through the extracellular matrix to approach the 
target cells in tissue. When arriving at the target site, ON conjugates have to cross the 
plasma membrane and the endosomal membrane to access their gene targets in the 
cytoplasm and/or nucleus of cells. (Partially adapted from Servier Medical Art, 
www.servier.com, with permission)
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GalNAc–siRNA conjugates. Structure of the triantennary GalNAc-siRNA conjugate [34].
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DPCs. In the original DPC, siRNA is linked to DPC polymer by disulfide bond (left) [70]. In 
the new generation of DPCs, DPC polymer and targeted siRNA are co-injected to achieve 
liver delivery (right) [75].
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Targeted HSA-ON conjugates. A morpholino ON was conjugated to a RGD peptide, and 
then, multiple RGD-oligo conjugates were linked to a single molecule of HSA via a 
reductively responsive linkage and this led to 13nm-sized NPs (left). The targeted NPs 
showed receptor-specific delivery to cancer cell (right upper) and excellent penetration into 
3-D tumor spheroids (right low).
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